MULTIPLE DRUG–RESISTANT TUBERCULOSIS - 09/09/11
Résumé |
The global tuberculosis epidemic will result in an estimated 90 million new cases and 30 million deaths during the current decade.44 Programmatic control of this devastating epidemic and clinical management of individual cases has been complicated in recent years by the widespread emergence of drug-resistant Mycobacterium tuberculosis. Rates of infection caused by multidrug-resistant (MDR) organisms, defined as resistance to at least isoniazid and rifampin, have reached critical levels in many areas of the United States and the world.5, 14 These cases of multidrug-resistant tuberculosis are associated with significantly higher rates of morbidity and mortality, and successful treatment typically necessitates prolonged courses of chemotherapy, measures to ensure patient adherence, and considerations of resectional surgery.23 Programmatic resources to address this emerging public health problem are frequently inadequate in the areas most profoundly affected by the epidemic.
Le texte complet de cet article est disponible en PDF.Plan
| Address reprint requests to Williamson Z. Bradford, MD, MPH, Division of Infectious Diseases, San Francisco General Hospital, Room 5K1, 1001 Potrero Avenue, San Francisco, CA 94110 This work was supported by Grant No. KO7 HL 3057–03 from the National Institutes of Health, and Grant No. PO HC96000892 from the Centers for Disease Control and Prevention. |
Vol 12 - N° 1
P. 157-172 - mars 1998 Retour au numéro
Article précédent
- BARTONELLA-ASSOCIATED INFECTIONS
- David H. Spach, Jane E. Koehler
- CAMPYLOBACTER JEJUNI INFECTION AS A CAUSE OF THE GUILLAIN-BARRÉ SYNDROME
- Ban Mishu Allos
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?